S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)

Avenue Therapeutics - ATXI Insider Trading & Ownership

$8.47
-6.03 (-41.59%)
(As of 10/5/2022 05:28 PM ET)
Add
Compare
Today's Range
$8.12
$10.50
50-Day Range
$3.21
$67.50
52-Week Range
$3.00
$27.75
Volume
2.70 million shs
Average Volume
874,515 shs
Market Capitalization
$12.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Avenue Therapeutics (NASDAQ:ATXI) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
2.70%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
0

ATXI Insider Buying and Selling by Quarter

Get ATXI Insider Trade Alerts

Want to know when executives and insiders are buying or selling Avenue Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.


Avenue Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2021Joseph Walter VazzanoCFOSell7,160$1.62$11,599.2065,252  
5/6/2021Neil HerskowitzDirectorBuy2,500$3.99$9,975.00  
5/6/2021Neil HerskowitzDirectorBuy2,500$3.99$9,975.00  
8/20/2020Joseph Walter VazzanoCFOSell3,840$12.13$46,579.20
3/9/2020Joseph Walter VazzanoCFOBuy1,500$7.99$11,985.0059,263  
2/27/2020Neil HerskowitzDirectorBuy2,400$8.20$19,680.00  
2/25/2020Joseph Walter VazzanoCFOBuy1,200$8.98$10,776.00
2/25/2020Neil HerskowitzDirectorBuy10,000$8.98$89,800.00  
9/12/2019Elizabeth Garrett IngramDirectorBuy16,000$6.27$100,320.0016,000  
8/9/2019Joseph Walter VazzanoCFOSell4,688$5.59$26,205.9259,038  
6/18/2019Neil HerskowitzDirectorBuy5,000$5.86$29,300.00  
4/15/2019Neil HerskowitzDirectorBuy1,000$4.52$4,520.00  
3/28/2019Neil HerskowitzDirectorBuy600$5.11$3,066.00  
2/25/2019Neil HerskowitzDirectorBuy5,000$5.46$27,300.00  
2/5/2019Neil HerskowitzDirectorBuy8,850$5.88$52,038.00  
1/30/2019Neil HerskowitzDirectorBuy650$5.91$3,841.50  
1/28/2019Neil HerskowitzDirectorBuy1,447$5.84$8,450.48  
12/10/2018Jeffrey PaleyDirectorBuy15,000$5.24$78,600.00  
12/3/2018Jeffrey PaleyDirectorBuy10,000$5.48$54,800.00  
6/8/2018Lindsay A. Md RosenwaldDirectorBuy5,234$4.34$22,715.56  
4/25/2018Neil HerskowitzDirectorBuy1,000$3.80$3,800.00  
10/17/2017Neil HerskowitzDirectorBuy1,000$5.01$5,010.00  
10/9/2017Neil HerskowitzDirectorBuy500$5.24$2,620.00  
(Data available from 1/1/2013 forward)












ATXI Insider Trading Activity - Frequently Asked Questions

Who is on Avenue Therapeutics's Insider Roster?

The list of insiders at Avenue Therapeutics includes Joseph Walter Vazzano, and Neil Herskowitz. Learn more on insiders at ATXI.

What percentage of Avenue Therapeutics stock is owned by insiders?

2.70% of Avenue Therapeutics stock is owned by insiders. Learn more on ATXI's insider holdings.

Which Avenue Therapeutics insiders have been buying company stock?

The following insider purchased ATXI shares in the last 24 months: Neil Herskowitz ($19,950.00).

How much insider buying is happening at Avenue Therapeutics?

Insiders have purchased a total of 5,000 ATXI shares in the last 24 months for a total of $19,950.00 bought.

Which Avenue Therapeutics insiders have been selling company stock?

The following insider sold ATXI shares in the last 24 months: Joseph Walter Vazzano ($11,599.20).

How much insider selling is happening at Avenue Therapeutics?

Insiders have sold a total of 7,160 Avenue Therapeutics shares in the last 24 months for a total of $11,599.20 sold.

This page (NASDAQ:ATXI) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.